U.S. markets open in 5 hours 48 minutes

MediciNova, Inc. (MNOV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1900+0.0300 (+1.39%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close2.1600
Bid0.0000 x 800
Ask0.0000 x 1000
Day's Range2.1700 - 2.2000
52 Week Range2.0800 - 4.6500
Avg. Volume23,822
Market Cap107.411M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.2720
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,100.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MNOV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MediciNova, Inc.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

    LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022. Yuichi Iwaki, MD, PhD, President and Chief Executive Of

  • GlobeNewswire

    MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

    LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a

  • Benzinga

    MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates

    MediciNova Inc (NASDAQ: MNOV) received a Notice of Allowance Canadian patent covering MN-001 (tipelukast) and MN-002 (a significant metabolite of MN-001) for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing triglyceride blood level, total cholesterol blood level, and low-density lipoprotein (L